DERMATITIS, ATOPIC

This study tests an investigational drug called JNJ-95597528 in 180 adults with moderate to severe atopic dermatitis (eczema). Participants receive either the drug or a placebo to see if it improves skin symptoms like redness, thickness, and itching. The main goal is to measure a…

This study is checking how safe and effective the drug Cibinqo (abrocitinib) is for people with moderate to severe atopic dermatitis, a type of eczema. About 1,100 participants in Korea will take the tablet by mouth and be followed for one year. Researchers will track side effect…

This study looks at how well the drug abrocitinib works for people with moderate-to-severe eczema (atopic dermatitis) who have already tried and not responded to, or couldn't tolerate, up to two other biologic treatments. Researchers will track 150 participants across the U.S. to…

This study tests a new drug called amlitelimab for people aged 12 and older with moderate-to-severe atopic dermatitis (eczema) that hasn't improved with other treatments. Participants will receive either the drug or a placebo by injection, while continuing to use topical steroids…

This study tests a new medicine called 611 in Chinese teenagers (ages 12-17) with moderate-to-severe atopic dermatitis (eczema). The drug targets a protein involved in inflammation to reduce skin redness, itching, and rashes. About 180 participants will receive either 611 or a pl…

This study follows 200 people aged 12 and older with moderate-to-severe eczema who are starting a new prescription of abrocitinib. Researchers will track how well the drug controls symptoms like itching and rash over 12 months in real-world settings. The goal is to see if the imp…

This study looks at how treatments for eczema (atopic dermatitis) change the types and amounts of bacteria on the skin. Researchers will compare skin samples from people with eczema and healthy volunteers over one year. The goal is to understand how treatments affect the skin's m…